NCT00007527View on ClinicalTrials.gov

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 31, 1999

Study Completion Date

January 31, 2002

Conditions
Opiate Dependence
Interventions
DRUG

naloxone

DRUG

buprenorphine

Trial Locations (2)

10010

Paul Casadonte, M.D. VAMC New York, New York

98108

Andrew Saxon, M.D.-Addictions Treatment (116ATC), Seattle

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Reckitt and Colman

OTHER

lead

US Department of Veterans Affairs

FED